Dr. David M. Jackman, MD

Dr. Jackman practices at Dana-Farber Cancer Institute in Boston, Massachusetts, part of Dana-Farber Cancer Institute.

Dr. Jackman's NPI, 1386622413, was assigned on January 9, 2006. Dr. Jackman graduated from The Warren Alpert Medical School of Brown University in 2000. Dr. Jackman holds Massachusetts license 221928.

Dr. Jackman's primary practice is Dana-Farber Cancer Institute, at 450 Brookline Avenue, Boston, MA 02115.

Dr. Jackman's primary practice is Dana-Farber Cancer Institute in Boston, Massachusetts, part of Dana-Farber Cancer Institute. Dr. Jackman is also affiliated with Brigham and Women's Hospital. The medical group on file is Binney Medical Group. Dmand AI also links Dr. Jackman to 1 more hospital, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Jackman practices, 4 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Jackman's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Jackman is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Jackman's licenses on file in 8 states: Massachusetts, Florida, Maine, Ohio, Connecticut, New Hampshire, Rhode Island and Vermont.

Dmand AI lists lung cancer and prostate cancer among the conditions Dr. Jackman treats.

CMS data shows 233 Medicare services from Dr. Jackman across 5 procedure codes in 2024, for 105 Medicare patients. Medicare paid $19,996 for them.

CMS counts 105 Medicare patients who saw Dr. Jackman in 2024. The largest group is 65 to 74, with 55 patients. 75% of them have cancer, and 75% have high blood pressure. 13% are also on Medicaid. Their average risk score is 2.62, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Jackman's median patient age at 73, with 64% women.

In 2024, Dr. Jackman wrote 108 Medicare Part D claims for 23 patients. 69% of them were for generic drugs. CMS names the drug for 12 of them, across 1 drug with 11 or more claims each, at $7,075 in total drug cost. In 2023, CMS named 37 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Jackman for performance year 2024, reported as part of a group. Dr. Jackman accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Jackman as offering telehealth.

Dmand AI links 80 papers to Dr. Jackman, published from 2007 to 2024. 2012 was the busiest year, with 8. The most frequent topics are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung and ErbB Receptors. Dr. Jackman has published most often in Clin Cancer Res. Dr. Jackman's most frequent co-authors are Bruce Evan Johnson, MD, Elizabeth H. Baldini, MD, MPH and Raymond H. Mak, MD.

Dmand AI links Dr. Jackman to 4 clinical trials, 4 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include Carcinoma, Non-Small-Cell Lung, Hematologic Neoplasms and Mesothelioma.

CMS Open Payments shows 32 general payments to Dr. Jackman from 5 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 92% of the total. Philips Electronics North America Corporation paid the most, $51,606.

Dr. Jackman graduated from The Warren Alpert Medical School of Brown University in 2000. Dr. Jackman is a member of ASCO.

Dr. Jackman is in network with 14 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 11. Check the plan with the practice before a visit.